Potential for tumor therapy with iodine-125 labeled immunoglobulins.
Because of the high intranuclear toxicity of Auger-electron emitters, the use of radioiodinated (123I, 125I) 5-iodo-2'-deoxyuridine (IUdR)-antibody conjugates for cancer therapy has been examined. The results have demonstrated that all the conditions necessary for labeling DNA in vivo are present: uptake of the radiolabeled immunoglobulin by target cells, its subsequent internalization, the degradation of the IUdR-protein conjugate by lysosomal enzymes, and the incorporation of the radionucleoside into DNA.
Adelstein
S J
SJ
Harvard Medical School, Boston, MA 02115.
Kassis
A I
AI
Baranowska-Kortylewicz
J
J
van den Abbeele
A D
AD
Mariani
G
G
Ito
S
S
D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use*; D007136:Immunoglobulins; D007167:Immunotherapy; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D009369:Neoplasms / Q000276:immunology / Q000532:radiotherapy*
D007136:Immunoglobulins; D007457:Iodine Radioisotopes; D007065:Idoxuridine